ZLDP.F Stock Overview
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Zealand Pharma A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.86.75 |
52 Week High | kr.111.44 |
52 Week Low | kr.32.42 |
Beta | 0.67 |
1 Month Change | -14.11% |
3 Month Change | 32.04% |
1 Year Change | 178.85% |
3 Year Change | 166.10% |
5 Year Change | n/a |
Change since IPO | 591.24% |
Recent News & Updates
Recent updates
Shareholder Returns
ZLDP.F | US Biotechs | US Market | |
---|---|---|---|
7D | -1.7% | -4.2% | -3.7% |
1Y | 178.8% | -2.0% | 20.5% |
Return vs Industry: ZLDP.F exceeded the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: ZLDP.F exceeded the US Market which returned 20.2% over the past year.
Price Volatility
ZLDP.F volatility | |
---|---|
ZLDP.F Average Weekly Movement | 17.3% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.4% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZLDP.F's share price has been volatile over the past 3 months.
Volatility Over Time: ZLDP.F's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 253 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Zealand Pharma A/S Fundamentals Summary
ZLDP.F fundamental statistics | |
---|---|
Market cap | US$5.32b |
Earnings (TTM) | -US$100.38m |
Revenue (TTM) | US$48.90m |
108.7x
P/S Ratio-53.0x
P/E RatioIs ZLDP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ZLDP.F income statement (TTM) | |
---|---|
Revenue | kr.342.79m |
Cost of Revenue | kr.688.10m |
Gross Profit | -kr.345.31m |
Other Expenses | kr.358.43m |
Earnings | -kr.703.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
Earnings per share (EPS) | -11.30 |
Gross Margin | -100.74% |
Net Profit Margin | -205.30% |
Debt/Equity Ratio | 0% |
How did ZLDP.F perform over the long term?
See historical performance and comparison